Cargando…

Improvement of asymmetric thyroid eye disease with teprotumumab

PURPOSE: Teprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J, Douglas, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132868/ https://www.ncbi.nlm.nih.gov/pubmed/33579690 http://dx.doi.org/10.1136/bjophthalmol-2020-318314

Ejemplares similares

Teprotumumab for thyroid eye disease: early response is not required for benefit
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
por: Douglas, Raymond S., et al.
Publicado: (2022)

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022)

Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
por: Douglas, Raymond S., et al.
Publicado: (2022)

Changing the face of thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022)

Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Early experience with teprotumumab for chronic thyroid eye disease
por: Ozzello, Daniel J., et al.
Publicado: (2020)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist
por: Chen, Hong, et al.
Publicado: (2015)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
por: Simmons, Brittany A., et al.
Publicado: (2022)

Teprotumumab in thyroid eye disease: wonder drug or great divider?
por: Perros, Petros, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

Effects of teprotumumab on patients with long-standing, active thyroid eye disease
por: Vinson, Kyle B., et al.
Publicado: (2022)

Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
por: Lin, Fei, et al.
Publicado: (2023)

A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
por: Safo, Myra B., et al.
Publicado: (2021)

Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
por: Douglas, Raymond S.
Publicado: (2018)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series
por: Chu, Matthew, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab
por: Otero-Marquez, Oscar, et al.
Publicado: (2022)

Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease
por: Najjar, Wassim, et al.
Publicado: (2022)

Elasomeran/teprotumumab: Thyroid-eye disease flare, diarrhoea and muscle spasms: case report
Publicado: (2022)

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab
por: Bowens, Brendan K., et al.
Publicado: (2022)

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study
por: O’Dell, Jordan Miller, et al.
Publicado: (2023)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
por: Bocklud, Brooke E, et al.
Publicado: (2023)

Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases
por: Chiou, Carolina A., et al.
Publicado: (2021)

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
por: Smith, Terry J.
Publicado: (2020)

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy
por: Adetunji, Modupe O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ke2n6hj1qiuf2nngkm462t7pve